FLUIDDA’s main acitivities consist of developing imaging biomarkers to enhance drug development and patient care. These biomarkers combine biomedical imaging and advanced engineering methods. It has been demonstrated in recent studies that this novel approach yields sensitive outcome parameters to detect physiological or clinical changes in patients following an intervention. This provides additional insight into the mode of action of the intervention and allows for optimization of the therapy and improved patient selection. To support the implementation of this novel method into clinical studies and clinical practice, FLUIDDA also offers a CRO service with the focus on imaging. A complete package can therefore be offered to the client from initial protocol writing to full data analysis using the advanced processing techniques. To offer a high quality service FLUIDDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. #FRI #FunctionalRespiratoryImaging
Looking for a particular FLUIDDA employee's phone or email?
The FLUIDDA annual revenue was $15.3 million in 2026.
Charles Mussche is the Vice President Clinical Applications of FLUIDDA.
25 people are employed at FLUIDDA.
FLUIDDA is based in New York, New York.
The NAICS codes for FLUIDDA are [33, 334].
The SIC codes for FLUIDDA are [38, 384].